

DIASTEREOSELECTIVE IODOAMIDATION OF 3-ACETOXYBUT-1-ENYLAMINES: SYNTHESIS OF 3-ACETOXY-4-iodo-2-(*p*-METHOXY-BENZYL)PYRROLIDINES

Kyu-Tae Chang,^b Ki Chang Jang,^d Ho-Yong Park,^b Young-Kook Kim,^c
Ki Hun Park,^{d*} and Woo Song Lee^{a*}


^aBK 21-School of Molecular Science & Department of Chemistry, Korea Advanced Institute of Science and Technology, Taejon 305-701, Korea

^bGenetic Resource Center and ^cLaboratory of Cardiovascular, Korea Research Institute of Bioscience and Biotechnology, Taejon 305-333, Korea


^dDepartment of Agricultural Chemistry, Gyeongsang National University, Chinju 660-701, Korea

Abstract-3 α -Acetoxy-4 α -iodo-2 α -(*p*-methoxybenzyl)pyrrolidine (**2**) and its enantiomer (**3**) were synthesized *via* diastereoselective iodoamidation, starting from D- or L-tyrosine. The key step contains unfavorable 5-*endo-trig* cyclization and the diastereoselective addition of ethynylmagnesium bromide to aldehydes (**9**) by the chelation-controlled Cram cyclic model.

The antibiotic (-)-anisomycin (**1**) possessing a pyrrolidine skeleton, which was isolated from various *Streptomyces* species, exhibits selective action against protozoa and several strains of fungi.¹ It also has been shown to act as an inhibitor of protein synthesis,¹ and it finds wide use in the treatment of trichomonas vaginitis and amebic dysentery.² Because of its biological activity, many chemists have reported chiral synthesis of (-)-anisomycin (**1**) employing naturally occurring starting materials such as carbohydrates,³ amino acids,⁴ L-tartaric acid or its esters.⁵ In this paper, we wish to report synthetic route for preparation of 3 α -acetoxy-4 α -iodo-2 α -(*p*-methoxybenzyl)pyrrolidine (**2**) and its enantiomer (**3**) through unfavorable 5-*endo-trig* cyclization, starting from D- or L-tyrosine. We also found the diastereoselective addition of ethynylmagnesium bromide to aldehyde by the chelation-controlled Cram cyclic model (Scheme 1).



Previously, we reported that 3-acetoxybut-1-enylamines (**4**) were easily transformed using iodine to pyrrolidine derivatives (**6**), precursors for aza sugars, *via* unfavorable 5-*endo-trig* cyclization of an intermediates (**5**) (Scheme 2).⁶



This tool should be allowed to apply for preparation of anisomycin derivatives. Compound (**8**) was synthesized easily by the usual method from commercially available D-tyrosine (**7**) in three high yielding steps. Then, we chose the 9-phenylfluoren-9-yl (Pf) group for protection of the amine since this protecting group has been shown to inhibit deprotonation at the α -position of α -amino ketones, esters, and aldehydes.⁷ Ester (**8**) was reduced with LiAlH₄ in THF to give alcohol, which was subjected by Swern oxidation to give aldehyde (**9**). Treatment of aldehyde (**9**) with ethynylmagnesium bromide in THF gave ethynyl alcohol (**10**) as a 10 : 1 mixture of *threo*- and *erythro*-isomers in 95% yield (*vide infra*), which could be isolated by column chromatography. Perhaps, the diastereoselectivity of the reaction of aldehyde (**9**) with ethynylmagnesium bromide is dependent on the presence of NHPf group. The *threo*-diastereoselectivity observed in the conversion of aldehyde (**9**) to **10** may be rationalized that the chelation-controlled Cram cyclic model⁸ is more favorable than the Felkin-Anh transition state model as shown in Figure 1.⁹ Thus, the attack by ethynylmagnesium bromide occurs from the less hindered side of the transition state (Figure 1) to give the *threo*-ethynyl alcohol (**10**) as the major product.





Figure 1 Transition State for *threo* Selectivity of Compound (**9**)

The ethynyl group of compound (**10**) was hydrogenated by treatment of compound (**10**) with Pd/BaSO₄ in the presence of quinoline to give the *threo*-allylic alcohol (**11**), which was protected with acetic anhydride to afford compound (**12**) in high yield. Compound (**12**) was treated with I₂ under biphasic conditions (saturated aq. NaHCO₃-THF-Et₂O = 2 : 1 : 1) at room temperature for 3 h to give the all *cis*-pyrrolidine (**2**) with a 26 : 1 ratio of the *cis*- and *trans*-isomers in high yield *via* a diastereoselective iodoamidation. Pyrrolidine (**3**) {[α]_D²¹ -22.9° (*c* 1.2, CHCl₃)} to be an enantiomer of **2** was also obtained with a 25 : 1 ratio of the *cis*- and *trans*-isomers from L-tyrosine using the standard condition (Scheme 3).



Scheme 3 Reagents and conditions: (a) TMSCl/MeOH/r.t.. (b) PfBr/Pb(NO₃)₂/Et₃N/CH₂Cl₂/rt. (c) MeI/K₂CO₃/acetone/reflux. (d) LiAlH₄/THF/rt. (e) (COCl)₂/DMSO/Et₃N/CH₂Cl₂/-78 °C-rt. (f) ethynylmagnesium bromide/THF/0 °C. (g) Pd/BaSO₄/quinoline/MeOH/r.t.. (h) Ac₂O/Et₃N/DMAP (cat.)/CH₂Cl₂/rt. (i) I₂/saturated aq. NaHCO₃ : THF : Et₂O = 2 : 1 : 1/rt.

Then, the stereochemistries of the products (**2**) and (**3**) were determined from their ¹H-NMR analysis based on the coupling constant values and 2D-nOe experiments.⁶

In summary we have reported that 3*α*-acetoxy-4*α*-iodo-2*α*-(*p*-methoxybenzyl)pyrrolidines (**2**) and (**3**) were obtained by key steps of a diastereoselective iodoamidation of 3-acetoxybut-1-enylamines (**12**) and

(14) and the diastereoselective addition of ethynylmagnesium bromide to aldehydes by the chelation-controlled Cram cyclic model, using a strong electron-donating group, 9-phenylfluoren-9-yl, on amine moiety.

EXPERIMENTAL

All non-aqueous reactions were carried out under nitrogen. THF was distilled from Na/benzophenone; CH₂Cl₂, Et₃N, and DMSO were distilled from CaH₂. Column chromatography was carried out using 230-400 mesh silica gel. Mps were measured on a Thomas-Hoover capillary apparatus and are uncorrected. ¹H- and ¹³C-NMR spectra were measured down field relative to tetramethylsilane in CDCl₃ unless otherwise noted (values in ppm); coupling constants were reported in hertz; ¹H-NMR, ¹³C-NMR and two-dimensional nuclear overhauser effect (2D nOe) experiments were conducted on a Bruker AW-500 spectrometer.

3-*p*-Methoxyphenyl-2α -*N*-9-phenylfluoren-9-ylamino-1-propanal (9)

D-Tyrosine (5.0 g, 27.60 mmol) was dissolved in TMSCl (10 mL) and MeOH (50 mL). After being stirred for 10 h at rt, the solution was evaporated, dried in vacuo for 10 h, and the salt was dissolved in CH₂Cl₂ (90 mL). 9-Phenylfluoren-9-yl bromide (11.5 g, 35.88 mmol), lead nitrate (11.9 g, 35.88 mmol) and Et₃N (7.7 mL, 55.2 mmol) were added. The mixture was stirred for 24 h at rt, and then it was filtered and chromatographed on silica gel (*n*-hexane : EtOAc = 20 : 1) to give *N*-protected methyl ester (10.86 g, 86%) as colorless needles. The *N*-protected methyl ester was dissolved in acetone (60 mL), and K₂CO₃ (4.9 g, 35.60 mmol) and iodomethane (7.4 mL, 118.7 mmol) were added. After refluxing for 36 h, the reaction was stopped by addition of 5% HCl. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried over MgSO₄. The solvent was removed under reduced pressure and the resulting crude product was chromatographed on silica gel (*n*-hexane : EtOAc = 6 : 1) to give the compound (8) (10.5 g, 98%) as colorless prisms.

To an ice-cooled suspension of LiAlH₄ (1.3 g, 34.91 mmol) in THF (116 mL) was added a solution of compound (8) (10.5 g, 23.27 mmol) in THF (100 mL). After being stirred for 10 min, the reaction mixture was quenched by addition of H₂O (10 mL), 15% aq. NaOH (10 mL), and Et₂O (100 mL), and then stirred for additional 20 min. The mixture was filtered, and the filtrate was concentrated. The residue was chromatographed on silica gel (*n*-hexane : EtOAc = 4 : 1) to give alcohol compound (8.8 g, 90%) as colorless prisms. To oxalyl chloride (4.6 mL, 52.35 mmol) in CH₂Cl₂ (170 mL) at -78 °C was added the solution of DMSO (5.9 mL, 83.8 mmol) in CH₂Cl₂ (50 mL) over 10 min and the mixture was stirred for 20 min. Alcohol (8.8 g, 20.94 mmol) in CH₂Cl₂ (80 mL) was added over 20 min and reacted for 20 min.

Finally, Et₃N (23.3 ml, 167.5 mmol) was added over 15 min, and the solution was allowed to warm over 60 min, at which time the solution was poured into Et₂O (200 mL) and 0.05 M phosphate buffer (pH 7.0) solution. The layers were separated, and the aqueous phase was extracted with EtOAc. The combined organic layers were washed successively with H₂O, 5% NaHCO₃ and brine, and dried over MgSO₄, concentrated, and chromatographed on silica gel (*n*-hexane : EtOAc = 10 : 1) to yield **9** (8.3 g, 95%) as colorless prisms, mp 38-40 °C (CH₂Cl₂/*n*-hexane); [α]_D²⁰ +1.6 ° (c 1.0, CHCl₃); IR (CHCl₃) 3310, 3068, 2940, 1726, 1614 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 2.53-2.62 (m, 2H), 2.68 (m, 1H), 2.76 (br s, 1H), 3.78 (s, 3H), 6.68-7.65 (m, 17H), 9.23 (d, *J* = 2.5 Hz, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 34.8, 53.3, 61.1, 70.9, 112.1, 117.8, 118.1, 122.9, 123.7, 124.1, 125.3, 125.8, 126.0, 126.3, 126.4, 126.9, 128.5, 138.6, 138.7, 142.3, 146.7, 146.8, 156.7, 201.0. Anal. Calcd for C₂₉H₂₅NO₂: C, 83.02; H, 6.01; N, 3.34. Found: C, 82.75; H, 5.71; N, 3.61.

4 α -N-9-Phenylfluoren-9-ylamino-3 α -hydroxy-5-*p*-methoxyphenyl-1-pentene (10)

To a solution of **9** (8.3 g, 19.89 mmol) in THF (100 mL) was added ethynylmagnesium bromide (79.6 mL, 39.8 mmol) (0.5 M solution in THF) at 0 °C. After being stirred for 30 min, the reaction mixture was quenched by addition of 5% HCl. The resulting mixture was extracted with EtOAc. The combined organic layers were with brine and dried over MgSO₄. The solvent was removed under reduced pressure and the resulting crude product was chromatographed on silica gel (*n*-hexane: EtOAc = 10 : 1) to give compound **(10)** (8.0 g, 90%) as colorless prisms, mp 63-65 °C (CH₂Cl₂/*n*-hexane); [α]_D²² +8.1 ° (c 2.0, CHCl₃); IR (KBr) 3450, 3310, 3070, 1610 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 2.31 (br s, 1H), 2.37 (d, *J* = 2.1 Hz, 1H), 2.40 (dd, *J* = 6.8, 13.4 Hz, 1H), 2.52 (ddd, *J* = 4.3, 6.6, 6.6 Hz, 1H), 2.63 (dd, *J* = 6.4, 13.5 Hz, 1H), 3.76 (s, 3H), 3.85 (dd, *J* = 2.2, 4.2 Hz, 1H), 6.73-7.67 (m, 18H); ¹³C-NMR (125 MHz, CDCl₃) δ 36.5, 55.3, 58.7, 64.4, 72.5, 74.0, 83.4, 113.8, 119.8, 120.0, 125.4, 125.8, 126.0, 127.2, 127.9, 128.2, 128.3, 128.5, 130.6, 140.2, 140.3, 145.4, 149.5, 149.6, 158.2. Anal. Calcd for C₃₁H₂₇NO₂: C, 83.56; H, 6.11; N, 3.15. Found: C, 83.81; H, 5.86; N, 2.95.

4 α -N-9-Phenylfluoren-9-ylamino-3 α -hydroxy-5-*p*-methoxyphenyl-1-pentene (11)

A solution of **10** (8.0 g, 17.9 mmol) in MeOH (45 mL) was hydrogenated under hydrogen atmosphere with Pd/BaSO₄ (10%, 0.8 mg) and quinoline (1.0 mL, 7.7 mmol) for 1 h. The mixture was filtered, the filtrate was evaporated, and the resulting crude product was chromatographed on silica gel (*n*-hexane: EtOAc = 10 : 1) to give compound **(11)** (7.6 g, 95%) as colorless prisms, mp 51-53 °C (CH₂Cl₂/*n*-hexane); [α]_D²³ -115.3 ° (c 2.0, CHCl₃); IR (CHCl₃) 3450, 3070, 1610 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 2.22 (dd, *J* = 5.1, 13.3 Hz, 1H), 2.32 (m, 2H), 2.48 (dd, *J* = 8.3, 13.3 Hz, 1H), 3.69 (m, 1H), 3.72 (s, 3H), 5.01 (dt, *J* = 10.6, 1.6 Hz, 1H), 5.12 (dt, *J* = 17.3, 1.6 Hz, 1H), 5.52 (ddd, *J* = 4.9, 10.6, 17.3 Hz, 1H), 6.62-7.71 (m, 18H); ¹³C-NMR (125 MHz, CDCl₃) δ 36.9, 54.2, 57.8, 71.1, 71.7, 112.7, 114.1, 118.9,

124.5, 125.0, 125.4, 126.2, 126.7, 126.9, 127.3, 127.4, 127.5, 129.4, 130.0, 138.7, 139.3, 139.7, 144.3, 148.1, 149.1, 157.0. Anal. Calcd for C₃₁H₂₉NO₂: C, 83.18; H, 6.54; N, 3.13. Found: C, 83.25; H, 6.30; N, 3.34.

4*α*-N-9-Phenylfluoren-9-ylamino-3*α*-acetoxy-5-*p*-methoxyphenyl-1-pentene (12)

To a solution of **11** (7.6 g, 17.01 mmol) in CH₂Cl₂ (100 mL) was added Et₃N (4.7 mL, 34.02 mmol) and acetic anhydride (3.2 mL, 34.02 mmol) in the presence of DMAP (cat.) at rt. After being stirred for 30 min, the reaction mixture was quenched by addition of 5% HCl and extracted with EtOAc. The combined organic layers were washed with brine and dried over MgSO₄. The resulting residue was chromatographed on silica gel (*n*-hexane : EtOAc = 5 : 1) to give compound (**12**) (8.0 g, 99%) as colorless prisms, mp 51-52 °C (CH₂Cl₂/*n*-hexane); [α]_D²³ -37.4 ° (*c* 5, CHCl₃); IR (3327, 3063, 3017, 2934, 1737, 1611, 1511; ¹H-NMR (500 MHz, CDCl₃) δ 1.94 (s, 3H), 2.22 (m, 2H), 2.45 (m, 2H), 3.73 (s, 3H), 4.83 (m, 1H), 5.10 (dt, *J* = 16.0, 1.6 Hz, 1H), 5.20 (dt, *J* = 10.8, 1.6 Hz, 1H), 5.91 (ddd, *J* = 5.1, 10.8, 17.3 Hz, 1H), 6.58-7.71 (m, 17H); ¹³C-NMR (125 MHz, CDCl₃) δ 20.9, 37.7, 55.2, 57.4, 72.7, 74.9, 113.7, 116.6, 119.7, 120.0, 125.3, 126.0, 126.2, 127.1, 127.7, 127.8, 128.1, 128.2, 128.4, 130.2, 131.0, 134.3, 140.2, 140.9, 145.6, 149.4, 149.9, 158.0, 169.5. Anal. Calcd for C₃₃H₃₁NO₃: C, 80.95; H, 6.38; N, 2.86. Found: C, 81.10; H, 6.62; N, 3.07.

N-9-Phenylfluoren-9-ylamino-3*α*-acetoxy-4*α*-iodo-2*α*-(*p*-methoxybenzyl)pyrrolidine (2)

To a solution of **12** (8.0 g, 16.84 mmol) in biphasic solvent (saturated aq. NaHCO₃ : THF : Et₂O = 2 : 1 : 1) was added I₂ (12.8 g, 50.52 mmol) at rt. After being stirred for 3 h, the reaction mixture was quenched by addition of saturated aqueous Na₂S₂O₃ solution, extracted with EtOAc. The combined organic layers were washed with brine, dried over MgSO₄, filtered and concentrated. The resulting residue was chromatographed on silica gel (*n*-hexane : EtOAc = 10 : 1) to give *cis*-pyrrolidine (**2**) (9.5 g, 92%) as colorless prisms, mp 72-73 °C (CH₂Cl₂/*n*-hexane); [α]_D²⁰ +55.0 ° (*c* 3, CHCl₃); IR (KBr) 3060, 3018, 2952, 1747, 1611, 1512 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 2.08 (s, 3H), 2.18 (dd, *J* = 3.3, 14.1 Hz, 1H), 2.65 (dd, *J* = 3.6, 9.3 Hz, 1H), 2.86 (dd, *J* = 11.0, 14.1 Hz, 1H), 3.17 (dd, *J* = 9.3, 11.1 Hz, 1H), 3.43 (ddd, *J* = 3.5, 7.1, 10.7 Hz, 1H), 3.55 (ddd, *J* = 3.6, 6.8, 10.9 Hz, 1H), 3.68 (s, 3H), 5.17 (t, *J* = 6.9 Hz, 1H), 6.57-7.75 (m, 17H); ¹³C-NMR (125 MHz, CDCl₃) δ 4.4, 21.4, 36.3, 55.6, 62.6, 63.1, 66.3, 76.2, 114.1, 120.5, 120.6, 127.0, 127.3, 127.6, 127.9, 128.4, 128.5, 128.6, 129.0, 129.3, 129.5, 129.7, 130.1, 130.6, 140.9, 141.3, 142.0, 146.2, 146.6, 158.2, 170.2. Anal. Calcd for C₃₃H₃₀NO₃I: C, 64.38; H, 4.92; N, 2.28. Found: C, 64.45; H, 5.12; N, 2.47.

ACNOWLEDGEMENTS

This work was supported by the Brain Korea 21 Project

REFERENCES

1. B. A. Sobin and F. W. Jr. Tanner, *J. Am. Chem. Soc.*, 1954, **76**, 4053; S. Ishida, O. Yamada, F. Futatsuya, K. Ito, H. Yamamoto, and K. Munakata, *Proc. Int. Congr. IAMS 1st 1974*, **3**, 641; A. Jimenez and D. Vazquez, In "Antibiotics"; ed. by F. E. Hahn, Springer Verlag: Berlin, 1979; pp. 1-19 and references cited therein; A. P. Grollman, *J. Bio. Chem.*, 1967, **242**, 3226.
2. V. M. Santander, A. B. Cue, J. G. H. Diaz, F. J. Balmis, G. Miranda, E. Urbina, J. Portilla, A. A. Plata, H. B. Zapata, V. A. Munoz, and L. M. Abreu, *Rev. Invest. Biol. Univ. Guadalajara*, 1961, **1**, 94; W. W. Frye, J. G. Mule, and C. Swartzwelder, *Antibiot. Ann.*, 1955, 820; T. Amstrong and O. Maria, *Ibid.*, 1955, 824.
3. J. P. H. Verheyden, A. C. Richardson, R. S. Bhatt, B. D. Grant, W. L. Fitch, and J. G. Moffatt, *Pure Appl. Chem.*, 1978, **50**, 1363; J. G. Buchanan, K. A. McLean, R. H. Wightman, and H. Paulsen, *J. Chem. Soc., Perkin Trans. 1*, 1985, 1463; H. H. Baer and M. Zamkane, *J. Org. Chem.*, 1988, **53**, 4786.
4. A. I. Meyers and B. Dupre, *Heterocycles*, 1987, **25**, 113; T. Shono and N. Kise, *Chem. Lett.*, 1987, 697; S. Jegham and B. C. Das, *Tetrahedron Lett.*, 1989, **29**, 4419.
5. C. M. Wong, J. Buccini, I. Chang, J. Te Raa, and R. Schwenk, *Can. J. Chem.*, 1969, **47**, 2421; I. Felner and K. Schenker, *Helv. Chim. Acta*, 1970, **53**, 754; H. Iida, N. Yamazaki, and C. Kibayashi, *J. Org. Chem.*, 1986, **51**, 1069; R. Ballini, E. Marcantoni, and M. Petrini, *J. Org. Chem.*, 1992, **57**, 1316.
6. W. S. Lee, K. C. Jang, J. H. Kim, and K. H. Park, *Chem. Commun.*, 1999, 251.
7. W. D. Lubell and H. Rapoport, *J. Am. Chem. Soc.*, 1987, **109**, 236.
8. D. J. Cram and D. R. Wison, *J. Am. Chem. Soc.*, 1963, **85**, 1245; P. Garner and S. Ramakanth, *J. Org. Chem.*, 1986, **51**, 2609; M. T. Reetz, M. W. Drewes, and A. Schmitz, *Angew. Chem., Int. Ed. Engl.*, 1987, **26**, 1141.
9. M. Cherest, H. Felkin, and N. Prudent, *Tetrahedron Lett.*, 1968, 2199; N. T. Anh and O. Eisenstein, *Nouv. J. Chem.*, 1977, **1**, 61; N. T. Anh, *Top. Curr. Chem.*, 1980, **88**, 144.